Skip to content
2000
image of Antiviral Activity of Synthetic Bis-Naphthoquinone (H-5) against Chikungunya Virus Replication

Abstract

Introduction

The chikungunya virus (CHIKV) is a significant public health concern, as it is one of the most critical re-emerging infections and still lacks specific treatment or vaccination measures.

Methods

In this study, bis-naphthoquinone (H-5) was tested in CHIKV-infected cells and mice. Several techniques were employed to understand the drug's mechanism of action.

Results

Cytotoxicity (CC50) and antiviral activity (EC50) tests revealed that H-5 presented low toxicity 1103 µM and good antiviral potential 0.96 µM. Virucidal test and time of addition of the compound to verify the mechanism of action presented good results. assays showed promise. In addition, synergism tests with Ribavirin indicated a strong synergistic effect.

Discussion

The antiviral effect associated with low toxicity demonstrates that the compound shows promise. In addition, the mechanism of action studies is crucial for the characterization of a good compound. Tests in mice demonstrated potential reduction of edema and favorable histological changes.

Conclusion

It is concluded that H-5 is a promising antiviral candidate against CHIKV.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ctmc/10.2174/0115680266358458251009100413
2026-04-06
2026-04-17

  • From This Site

    /content/journals/ctmc/10.2174/0115680266358458251009100413
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Ahola T. Couderc T. Ng L.F.P. Hallengärd D. Powers A. Lecuit M. Esteban M. Merits A. Roques P. Liljeström P. Therapeutics and vaccines against chikungunya virus. Vector Borne Zoonotic Dis. 2015 15 4 250 257 10.1089/vbz.2014.1681 25897811
    [Google Scholar]
  2. Caglioti C. Lalle E. Castilletti C. Carletti F. Capobianchi M.R. Bordi L. Chikungunya virus infection: An overview. New Microbiol. 2013 36 3 211 227 23912863
    [Google Scholar]
  3. Current ICTV Taxonomy Release 2023 Available from: https://ictv.global/taxonomy
  4. Chazal N. Briant L. Chikungunya Virus Entry and Replication. Chikungunya Virus. Springer 2016 127 148 10.1007/978‑3‑319‑42958‑8_8
    [Google Scholar]
  5. Jaffar-Bandjee M.C. Ramful D. Gauzere B.A. Hoarau J.J. Krejbich-Trotot P. Robin S. Ribera A. Selambarom J. Gasque P. Emergence and clinical insights into the pathology of Chikungunya virus infection. Expert Rev. Anti Infect. Ther. 2010 8 9 987 996 10.1586/eri.10.92 20818943
    [Google Scholar]
  6. Her Z. Teng T.S. Tan J.J.L. Teo T.H. Kam Y.W. Lum F.M. Lee W.W.L. Gabriel C. Melchiotti R. Andiappan A.K. Lulla V. Lulla A. Win M.K. Chow A. Biswas S.K. Leo Y.S. Lecuit M. Merits A. Rénia L. Ng L.F.P. Loss of TLR3 aggravates CHIKV replication and pathology due to an altered virus‐specific neutralizing antibody response. EMBO Mol. Med. 2015 7 1 24 41 10.15252/emmm.201404459 25452586
    [Google Scholar]
  7. Sahadeo N. Mohammed H. Allicock O.M. Auguste A.J. Widen S.G. Badal K. Pulchan K. Foster J.E. Weaver S.C. Carrington C.V.F. Molecular characterization of chikungunya virus infections in Trinidad and comparison of clinical and laboratory features with dengue and other acute febrile cases. PLoS Negl. Trop. Dis. 2015 9 11 e0004199 10.1371/journal.pntd.0004199 26580074
    [Google Scholar]
  8. Thiberville S.D. Moyen N. Dupuis-Maguiraga L. Nougairede A. Gould E.A. Roques P. de Lamballerie X. Chikungunya fever: Epidemiology, clinical syndrome, pathogenesis and therapy. Antiviral Res. 2013 99 3 345 370 10.1016/j.antiviral.2013.06.009 23811281
    [Google Scholar]
  9. Santos A.S. Lima M. Ferreira M. Biological activities of naphthoquinones: Antiviral and antibacterial properties. J. Antimicrob. Chemother. 2019 74 9 2511 2517
    [Google Scholar]
  10. Haviernik J. Štefánik M. Fojtíková M. Kali S. Tordo N. Rudolf I. Hubálek Z. Eyer L. Ruzek D. Arbidol (Umifenovir): A broad-spectrum antiviral drug that inhibits medically important arthropod-borne flaviviruses. Viruses 2018 10 4 184 10.3390/v10040184 29642580
    [Google Scholar]
  11. Gonzaga D. Gomes R. Marra R. da Silva F. Gomes M. Ferreira D. Santos R. Pinto A. Ratcliffe N.A. Cirne-Santos C. Barros C. Ferreira V. Paixão I.C. Inhibition of Zika virus replication by synthetic bis-naphthoquinones. J. Braz. Chem. Soc. 2019 30 1697 1706 10.21577/0103‑5053.20190071
    [Google Scholar]
  12. Sebaugh J.L. Guidelines for accurate EC50/IC50 estimation. Pharm. Stat. 2011 10 2 128 134 10.1002/pst.426 22328315
    [Google Scholar]
  13. Cirne-Santos C.C. Barros C.S. Nogueira C.C.R. Azevedo R.C. Yamamoto K.A. Meira G.L.S. Vasconcelos Z.F.M. Ratcliffe N.A. Teixeira V.L. Schmidt-Chanasit J. Ferreira D.F. Paixão I.C.N.P. Inhibition by marine algae of chikungunya virus isolated from patients in a recent disease outbreak in Rio de Janeiro. Front. Microbiol. 2019 10 2426 10.3389/fmicb.2019.02426 31708898
    [Google Scholar]
  14. Caroline S.B. Max W.L.G. Rafaela S.P.G. Vanessa M. Caio C.R.N. Claudio C.C-S. Valeria G. Carla E.C.P. Valeria L.T. Izabel C.N.P.P. Acute toxicity evaluation of ethanol extract of red algae, Osmundaria obtusiloba, in BALB/c mice. J. Med. Plants Res. 2018 12 17 217 221 10.5897/JMPR2018.6582
    [Google Scholar]
  15. Koutsoni O. Karampetsou K. Dotsika E. In vitro screening of antileishmanial activity of natural product compounds: determination of IC50, CC50, and SI values. Bio Protoc. 2019 9 21 e3410 e3410 10.21769/BioProtoc.3410 33654910
    [Google Scholar]
  16. Tisseh Z.N. Bazgir A. An efficient, clean synthesis of 3,3′-(arylmethylene)bis(2-hydroxynaphthalene-1,4-dione) derivatives. Dyes Pigments 2009 83 2 258 261 10.1016/j.dyepig.2008.09.003
    [Google Scholar]
  17. Musumeci G. Past, present and future: Overview on histology and histopathology. J. Histol Histopathol 2014 1 1 5 10.7243/2055‑091X‑1‑5
    [Google Scholar]
  18. Das T. Jaffar-Bandjee M.C. Hoarau J.J. Krejbich Trotot P. Denizot M. Lee-Pat-Yuen G. Sahoo R. Guiraud P. Ramful D. Robin S. Alessandri J.L. Gauzere B.A. Gasque P. Chikungunya fever: CNS infection and pathologies of a re-emerging arbovirus. Prog. Neurobiol. 2010 91 2 121 129 10.1016/j.pneurobio.2009.12.006 20026374
    [Google Scholar]
  19. Davuluri K.S. Ghanghav R. Ahire G. Kakade M. Cherian S. Alagarasu K. Parashar D. Repurposed drugs in combinations exert additive anti-chikungunya virus activity: An in-vitro study. Virol. J. 2024 21 1 5 10.1186/s12985‑023‑02271‑0 38178163
    [Google Scholar]
  20. Kuo S.C. Wang Y.M. Ho Y.J. Chang T.Y. Lai Z.Z. Tsui P.Y. Wu T.Y. Lin C.C. Suramin treatment reduces chikungunya pathogenesis in mice. Antiviral Res. 2016 134 89 96 10.1016/j.antiviral.2016.07.025 27577529
    [Google Scholar]
  21. Weaver S.C. Osorio J.E. Livengood J.A. Chen R. Stinchcomb D.T. Chikungunya virus and prospects for a vaccine. Expert Rev. Vaccines 2012 11 9 1087 1101 10.1586/erv.12.84 23151166
    [Google Scholar]
  22. Gasmi A. Peana M. Noor S. Lysiuk R. Menzel A. Gasmi Benahmed A. Bjørklund G. Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story. Appl. Microbiol. Biotechnol. 2021 105 4 1333 1343 10.1007/s00253‑021‑11094‑4 33515285
    [Google Scholar]
  23. Ooi E.E. Goh K.J. Tan H.C. Antiviral resistance mechanisms of Zika virus. Antiviral Res. 2017 139 70 77
    [Google Scholar]
  24. Lima A. Silva C. Costa S. Anticancer activity of naphthoquinone derivatives: A review of mechanisms and potential. Anticancer. Agents Med. Chem. 2017 17 5 731 744
    [Google Scholar]
  25. Puntasecca C.J. King C.H. LaBeaud A.D. Measuring the global burden of chikungunya and Zika viruses: A systematic review. PLoS Negl. Trop. Dis. 2021 15 3 e0009055 10.1371/journal.pntd.0009055 33661908
    [Google Scholar]
  26. Ventura Pinto A. Lisboa de Castro S. The trypanocidal activity of naphthoquinones: A review. Molecules 2009 14 11 4570 4590 10.3390/molecules14114570 19924086
    [Google Scholar]
  27. Tahir ul Qamar, Muhammad; Shokat, Zunaira; Muneer, Iqra; Ashfaq, Usman Ali; Javed, Hamza; Anwar, Fatima; Bari, Ammar; Zahid, Bushra; Saif, Saba Peptide vaccine against chikungunya virus: Immuno-informatics combined with molecular docking approach. J. Transl. Med. 2018 16 1 298 298 10.1186/s12967‑018‑1675‑2
    [Google Scholar]
  28. Plante K.S. Rossi S.L. Bergren N.A. Seymour R.L. Weaver S.C. Extended preclinical safety, efficacy and stability of a live-attenuated chikungunya vaccine candidate. PLoS Negl. Trop. Dis. 2015 9 9 e0004007 10.1371/journal.pntd.0004007 26340754
    [Google Scholar]
  29. Chang L.J. Dowd K.A. Mendoza F.H. Saunders J.G. Sitar S. Plummer S.H. Yamshchikov G. Sarwar U.N. Hu Z. Enama M.E. Bailer R.T. Koup R.A. Schwartz R.M. Akahata W. Nabel G.J. Mascola J.R. Pierson T.C. Graham B.S. Ledgerwood J.E. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet 2014 384 9959 2046 2052 10.1016/S0140‑6736(14)61185‑5 25132507
    [Google Scholar]
  30. Mallilankaraman K. Ledgerwood J.E. Chikungunya virus-like particle vaccine elicits protective immunity in nonhuman primates. J. Infect. Dis. 2011 204 6 854 862 21849282
    [Google Scholar]
  31. Akahata W. Yang Z.Y. Andersen H. Sun S. Holdaway H.A. Kong W.P. Lewis M.G. Higgs S. Rossmann M.G. Rao S. Nabel G.J. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat. Med. 2010 16 3 334 338 10.1038/nm.2105 20111039
    [Google Scholar]
  32. Wressnigg N. A randomized, double-blind, placebo-controlled, phase 1 study of the safety and immunogenicity of a recombinant live-attenuated chikungunya vaccine candidate in healthy adults. Vaccine 2013 31 44 5145 5152
    [Google Scholar]
  33. Roques Pierre Ljungberg Karl van der Werf Sylvie Compans Richard W. Barban Veronique Klupp Barbara G. de Haan Cornelis A.M. Rimmelzwaan Guus F. Attenuated and vectored vaccines protect nonhuman primates against chikungunya virus. J. Clin. Invest. 2014 124 6 3257 3267 10.1172/JCI74627
    [Google Scholar]
  34. García-Arriaza J. Cepeda V. Hallengärd D. Sorzano C.Ó.S. Kümmerer B.M. Liljeström P. Esteban M. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. J. Virol. 2014 88 6 3527 3547 10.1128/JVI.03418‑13 24403588
    [Google Scholar]
  35. Hallengärd D. Lum F.M. Kümmerer B.M. Lulla A. Lulla V. García-Arriaza J. Fazakerley J.K. Roques P. Le Grand R. Merits A. Ng L.F.P. Esteban M. Liljeström P. Prime-boost immunization strategies against Chikungunya virus. J. Virol. 2014 88 22 13333 13343 10.1128/JVI.01926‑14 25210177
    [Google Scholar]
  36. Kim E. Okada K. Kenniston T. Raj V.S. AlHajri M.M. Farag E.A.B.A. AlHajri F. Osterhaus A.D.M.E. Haagmans B.L. Gambotto A. Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice. Vaccine 2014 32 45 5975 5982 10.1016/j.vaccine.2014.08.058 25192975
    [Google Scholar]
  37. García-Arriaza J. A recombinant MVA vector expressing chikungunya virus-like particles is highly immunogenic and protects mice against lethal challenge with chikungunya virus. J. Virol. 2014 88 6 3527 3537 24403588
    [Google Scholar]
  38. Metz S.W. Martina B.E. van den Doel P. Chikungunya virus-like particles are more immunogenic than native virus particles in mice due to a higher stability of the structural proteins. PLoS Negl. Trop. Dis. 2013 7 7 e2471 10.1016/j.vaccine.2013.09.045
    [Google Scholar]
  39. Parashar D. Cherian S. Antiviral perspectives for chikungunya virus. Future Virol. 2014 9 5 513 530 25214882
    [Google Scholar]
  40. Kumar S. Antiviral phosphorodiamidate morpholino oligomers are protective against intracerebral chikungunya virus infection in neonatal mice. Sci. Rep. 2015 5 12727 10.1038/srep12727 26224141
    [Google Scholar]
  41. Kovacikova K. van Hemert M.J. Small-molecule inhibitors of chikungunya virus. Antimicrob. Agents Chemother. 2020 64 12 e01788 e20 10.1128/AAC.01788‑20 32928738
    [Google Scholar]
  42. Poo Y.S. Rudd P.A. Gardner J. Wilson J.A.C. Larcher T. Colle M.A. Le T.T. Nakaya H.I. Warrilow D. Allcock R. Bielefeldt-Ohmann H. Schroder W.A. Khromykh A.A. Lopez J.A. Suhrbier A. Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection. PLoS Negl. Trop. Dis. 2014 8 12 e3354 10.1371/journal.pntd.0003354 25474568
    [Google Scholar]
  43. Wang G. Screening of FDA-approved drugs for inhibitors of Zika virus infection. J. Virol. 2017 91 6 e01023 e16
    [Google Scholar]
  44. Labadie K. Larcher T. Joubert C. Mannioui A. Delache B. Brochard P. Guigand L. Dubreil L. Lebon P. Verrier B. de Lamballerie X. Suhrbier A. Cherel Y. Le Grand R. Roques P. Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. J. Clin. Invest. 2010 120 3 894 906 10.1172/JCI40104 20179353
    [Google Scholar]
  45. Plante K.S. Novel chikungunya vaccine candidate with an IRES-based attenuation mechanism. J. Infect. Dis. 2011 203 5 749 758 21829348
    [Google Scholar]
  46. Morrison T.E. Whitmore A.C. Shabman R.S. Lidbury B.A. Mahalingam S. Heise M.T. Characterization of Ross River virus tropism and virus-induced inflammation in a mouse model of viral arthritis and myositis. J. Virol. 2006 80 2 737 749 10.1128/JVI.80.2.737‑749.2006 16378976
    [Google Scholar]
  47. Powers A.M. Aguilar P. Chandler L.J. Brault A.C. Meakins T.A. Watts D. Russell K.L. Olson J. Vasconcelos P.F.C. Da Rosa A.T. Weaver S.C. Tesh R.B. Genetic relationships among Mayaro and Una viruses suggest distinct patterns of transmission. Am. J. Trop. Med. Hyg. 2006 75 3 461 469 10.4269/ajtmh.2006.75.461 16968922
    [Google Scholar]
  48. Muthumani K. Falzarano D. Reuschel E.L. Tingey C. Flingai S. Villarreal D.O. Wise M. Patel A. Izmirly A. Aljuaid A. Seliga A.M. Soule G. Morrow M. Kraynyak K.A. Khan A.S. Scott D.P. Feldmann F. LaCasse R. Meade-White K. Okumura A. Ugen K.E. Sardesai N.Y. Kim J.J. Kobinger G. Feldmann H. Weiner D.B. A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci. Transl. Med. 2015 7 301 301ra132 10.1126/scitranslmed.aac7462 26290414
    [Google Scholar]
  49. Fischer M. Staples J.E. Notes from the field: Chikungunya virus spreads in the Americas - Caribbean and South America, 2013-2014. MMWR Morb. Mortal. Wkly. Rep. 2014 63 22 500 501 24898168
    [Google Scholar]
  50. Pialoux G. Gaüzère B.A. Jauréguiberry S. Strobel M. Chikungunya, an epidemic arbovirosis. Lancet Infect. Dis. 2007 7 5 319 327 10.1016/S1473‑3099(07)70107‑X 17448935
    [Google Scholar]
  51. Schwartz O. Albert M.L. Biology and pathogenesis of chikungunya virus. Nat. Rev. Microbiol. 2010 8 7 491 500 10.1038/nrmicro2368 20551973
    [Google Scholar]
  52. Staples J.E. Initial and long-term management of patients with chikungunya virus infection. MMWR Morb. Mortal. Wkly. Rep. 2016 65 3 1 12 10.15585/mmwr.mm6503e3er 26820387
    [Google Scholar]
  53. Burt F.J. Rolph M.S. Rulli N.E. Mahalingam S. Heise M.T. Chikungunya: A re-emerging virus. Lancet 2012 379 9816 662 671 10.1016/S0140‑6736(11)60281‑X 22100854
    [Google Scholar]
  54. Morrison T.E. Reemergence of chikungunya virus. J. Virol. 2014 88 20 11644 11647 10.1128/JVI.01432‑14 25078691
    [Google Scholar]
  55. Voss J.E. Vaney M.C. Duquerroy S. Vonrhein C. Girard-Blanc C. Crublet E. Thompson A. Bricogne G. Rey F.A. Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography. Nature 2010 468 7324 709 712 10.1038/nature09555 21124458
    [Google Scholar]
  56. Lum F.M. Ng L.F.P. Cellular and molecular mechanisms of chikungunya pathogenesis. Antiviral Res. 2015 120 165 174 10.1016/j.antiviral.2015.06.009 26092642
    [Google Scholar]
  57. Chen R. Mukhopadhyay S. Merits A. Bolling B. Nasar F. Coffey L.L. Powers A. Weaver S.C. ICTV virus taxonomy profile. Togaviridae. J. Gen. Virol. 2018 99 6 761 762 10.1099/jgv.0.001072 29745869
    [Google Scholar]
  58. Agarwal R. Chikungunya vaccine: Developments and challenges. Expert Rev. Vaccines 2017 16 12 1291 1301
    [Google Scholar]
  59. Limonta D. Dyna-Dagman L. Branton W. Mancinelli V. Makio T. Wozniak R.W. Power C. Hobman T.C. Nodosome inhibition as a novel broad-spectrum antiviral strategy against arboviruses, enteroviruses, and SARS-CoV-2. Antimicrob. Agents Chemother. 2021 65 8 e00491 e21 10.1128/AAC.00491‑21 34001511
    [Google Scholar]
  60. Antivirals against arboviruses. Liu, B.M., Ed.; Virus. 2021 Available from: https://www.mdpi.com/journal/viruses/special_issues/Antivirals_Arboviruses
  61. Neyts J. Challenges in combating arboviral infections. Nat. Commun. 2024 15 1 3350 10.1038/s41467‑024‑47161‑3 38637542
    [Google Scholar]
/content/journals/ctmc/10.2174/0115680266358458251009100413
Loading
Antiviral Activity of Synthetic Bis-Naphthoquinone (H-5) against Chikungunya Virus Replication
Bentham Science Publishers ; https://doi.org/10.2174/0115680266358458251009100413
/content/journals/ctmc/10.2174/0115680266358458251009100413
/content/journals/ctmc/10.2174/0115680266358458251009100413
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: Chikungunya ; Antiviral ; Cell culture ; Alphaviruses ; Naphthoquinone ; Arbovirus

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test